Gland Pharma Limited has convened its 48th Annual General Meeting (AGM) for Tuesday, August 25, 2026, at 11:00 A.M. IST, to be held through Video Conferencing (VC) / Other Audio-Visual Means (OAVM) in compliance with Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and applicable Ministry of Corporate Affairs (MCA) circulars. The deemed venue for the meeting is the company's Corporate Office at Plot No. 11 & 84, TSIIC, Phase-IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad. The AGM Notice along with the Annual Report for FY 2025-26 has been dispatched electronically to members who have registered their email addresses.

Key AGM Details

The following table summarises the important dates and parameters for the 48th AGM:

Agenda: Dividend and Director Reappointments

The ordinary business at the AGM includes adoption of audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026, along with the Board's Report and Auditor's Report. The Board of Directors has recommended a final dividend of ₹20 per equity share (face value ₹1 each), representing 2000%, for FY 2025-26, subject to shareholder approval. The record date for determining dividend eligibility is August 11, 2026, and payment will be made within 30 days of shareholder approval.

The AGM will also consider the reappointment of two Non-Executive and Non-Independent Directors retiring by rotation:

Both directors draw no remuneration from the Company in their capacity as Non-Executive Directors.

FY 2025-26 Financial Performance Highlights

The Annual Report accompanying the AGM Notice reflects strong operational and financial performance for FY 2025-26. The following table presents key consolidated financial metrics:

Revenue from operations grew 14.5% year-on-year, driven by volume expansion, new contract wins, and higher contribution from differentiated products, particularly in the U.S. market. EBITDA grew by 28% and the Interest Coverage Ratio improved by 62% to 133.85 times. The base business (excluding Cenexi) recorded revenues of ₹45,613 Mn with an EBITDA margin of 36%.

Regulatory Pipeline and Strategic Highlights

During FY 2025-26, Gland Pharma filed 24 ANDAs and received 28 approvals, taking cumulative U.S. ANDA filings to 388 (337 approved, 51 pending). The company launched 31 molecules in the U.S. and rolled out 36 molecules across regulated markets. The GLP-1 platform saw the partnered Liraglutide product expanded to the UK and Australia, with cartridge and pen capacity scaled from ~40 million to 140 million units per year. The company also advanced 15 products into co-development and filed 21 RTU infusion bag products, of which 18 have received approvals.

Shareholder and Document Access

In accordance with SEBI (LODR) (Third Amendment) Regulations, 2024, the AGM Notice and Annual Report for FY 2025-26 are being sent only through electronic mode. Members who have not registered their email IDs will receive a letter with a weblink and QR code to access the documents online. Physical shareholders must submit KYC details to the Registrar and Transfer Agent, MUFG Intime India Private Limited, C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai – 400 083. Demat shareholders should update their KYC with their respective Depository Participants. AGM documents are also available on the company's website ( www.glandpharma.com ), BSE ( www.bseindia.com ), NSE ( www.nseindia.com ), and NSDL ( www.evoting.nsdl.com ).

For TDS-related submissions, members are required to upload requisite forms on or before August 16, 2026. The Scrutinizer for the e-voting process is Ms. D Soumya, Associate Partner, RVR & Associates (Membership No. F11754; CP No. 13199). Voting results will be declared after the AGM and published on the company's website and the NSDL platform.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE068V01023/194b8488-f37c-4e0a-a510-1dccacff9d72.pdf

Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Sugammadex Injection. The regulatory clearance covers two strengths: 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. This approval allows the company to commercialize a generic version of the reference listed drug (RLD), BRIDION® Injection, manufactured by Merck Sharp & Dohme LLC. The product is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients undergoing surgery.

According to data from IQVIA, the Sugammadex product category generated US sales of approximately USD 1.6 billion for the twelve months ending April 2026. Gland Pharma has successfully launched the product on Day 1 through its designated marketing partner, positioning itself to capture market share in this high-value therapeutic segment immediately upon approval.

Product Details

The approved formulation is described as bioequivalent and therapeutically equivalent to the RLD. The specific configurations approved by the USFDA are outlined below:

Regulatory Disclosure

The announcement was made pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The press release was issued on July 29, 2026, and signed by Sampath Kumar Pallerlamudi, Company Secretary & Compliance Officer.

Market Significance

The immediate launch of the product highlights Gland Pharma's operational readiness in the sterile injectables segment. By entering a market with USD 1.6 billion in recent annual sales, the company targets a significant revenue stream without the delay typically associated with post-approval supply chain ramp-ups. The reliance on a marketing partner for Day 1 launch reflects a strategic focus on manufacturing efficiency while leveraging external networks for distribution, a model consistent with its broader business-to-business (B2B) approach in global markets.